Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
Julphar
Citi
Deloitte
Covington
UBS
Fish and Richardson
Cipla
Accenture
QuintilesIMS

Generated: February 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,720,004

« Back to Dashboard

Which drugs does patent 6,720,004 protect, and when does it expire?

Patent 6,720,004 protects DEPAKOTE ER and is included in one NDA.

Protection for DEPAKOTE ER has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-seven patent family members in twenty-seven countries.
Summary for Patent: 6,720,004
Title: Controlled release formulation of divalproex sodium
Abstract:A new oral polymeric controlled release formulation suitable for the once-a-day administration of valproate compounds, such as divalproex sodium, has been discovered. This formulation exhibits significant advantages over the sustained release valproate formulations of the prior art. This formulation minimizes the variation between peak and trough plasma levels of valproate over a 24 hour dosing period. This formulation follows a zero-order release pattern thus producing essentially flat plasma levels of valproate, once steady-state levels have been achieved. This results in a significantly lower incidence of side effects for patients consuming such a formulation.
Inventor(s): Qiu; Yihong (Gumee, IL), Bollinger; J. Daniel (Libertyville, IL), Dutta; Sandeep (Waukegan, IL), Cheskin; Howard S. (Glencoe, IL), Engh; Kevin R. (Kenosha, WI), Poska; Richard P. (Mundelein, IL)
Assignee: Abbott Laboratories (Abbott Park, IL)
Application Number:10/215,141
Patent Claim Types:
see list of patent claims
Formulation; Compound; Device; Dosage form;

Drugs Protected by US Patent 6,720,004

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Abbvie DEPAKOTE ER divalproex sodium TABLET, EXTENDED RELEASE;ORAL 021168-002 May 31, 2002 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Abbvie DEPAKOTE ER divalproex sodium TABLET, EXTENDED RELEASE;ORAL 021168-001 Aug 4, 2000 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,720,004

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,528,091 Controlled release formulation of divalproex sodium ➤ Sign Up
6,419,953 Controlled release formulation of divalproex sodium ➤ Sign Up
6,511,678 Controlled release formulation of divalproex sodium ➤ Sign Up
6,528,090 Controlled release formulation of divalproex sodium ➤ Sign Up
6,713,086 Controlled release formulation of divalproex sodium ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,720,004

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 021443 ➤ Sign Up
Austria 254907 ➤ Sign Up
Austria 275398 ➤ Sign Up
Australia 2002239260 ➤ Sign Up
Australia 2478900 ➤ Sign Up
Bulgaria 105665 ➤ Sign Up
Brazil 9916361 ➤ Sign Up
Canada 2330480 ➤ Sign Up
Canada 2341803 ➤ Sign Up
Canada 2341805 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Queensland Health
McKinsey
Julphar
Cipla
QuintilesIMS
Fish and Richardson
Daiichi Sankyo
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot